Article Download
How to Monitor and Validate CAR T-Cell Therapies During Manufacturing and Beyond
Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of blood cancers. Yet, as regulatory agencies approve more of these groundbreaking therapies for clinical use, questions about safety and efficacy linger.
In this article, discover how Droplet Digital™ PCR (ddPCR™) technology provides a robust and sensitive method needed for monitoring and validating CAR T-cell therapies during manufacturing, including:
- How to address safety issues in CAR T-cell manufacture with ddPCR technology
- Why it's important to measure CAR gene copy numbers in CAR T-cell manufacturing, and how the absolute quantification of ddPCR technology can track CAR gene copy numbers accurately and reproducibly
- Ways ddPCR technology can be used to monitor clinical responses to CAR T-cell therapies
Download the Article
Share a little information with us to access the entire article now.
Content you'll also find interesting
Recommended Features
-
Image
Monitoring CAR T-Cell Therapy Quality with Droplet Digital™ PCR
Understand how ddPCR technology provides the sensitivity, precision, and versatility needed to improve quality control for the CAR T-cell manufacturing process.
-
Image
Transitioning Your Assay from Quantitative PCR to Droplet Digital™ PCR
Get guidance on how to transition from qPCR to ddPCR technology and the differences and similarities to consider between the two methods based on AAV titering assay study.
-
Image
Droplet Digital™ PCR (ddPCR™) Is Well Suited for Quantifying Transgene Copy Number
Discover why CAR T-cell therapy is so exciting, note some common hurdles in development and manufacturing, and how ddPCR technology is a solution for some of these issues.
